Emmaus Life Sciences, Inc. Quarterly report [Sections 13 or 15(d)]

Selected Financial Statement - Liabilities (Tables)

6 Months Ended

Jun. 30, 2025

Accounts payable and accrued expenses consisted of the following at June 30, 2025 and December 31, 2024 (in thousands):


	June 30, 2025		December 31, 2024
Accounts payable:
Clinical and regulatory expenses	$	540	$	452
Professional fees		661		904
Selling expenses		1,420		1,553
Manufacturing costs		209		706
Non-employee director compensation		982		966
Other vendors		750		594
Total accounts payable		4,562		5,175
Accrued interest payable, related parties		1,372		1,145
Accrued interest payable		4,407		2,874
Accrued expenses:
Payroll expenses		545		323
Government rebates and other rebates		8,130		7,229
Other accrued expenses		357		180
Total accrued expenses		9,032		7,732
Total accounts payable and accrued expenses	$	19,373	$	16,926

Other current liabilities consisted of the following at June 30, 2025 and December 31, 2024 (in thousands):


	June 30, 2025		December 31, 2024
Trade discount	$	3,000	$	5,000
Unearned revenue (a)		10,000		10,000
Other current liabilities		1,139		1,557
Total other current liabilities	$	14,139	$	16,557

(a) Refer to Note 3 for information regarding to due to Telcon.

Other long-term liabilities consisted of the following at June 30, 2025 and December 31, 2024 (in thousands):


	June 30, 2025		December 31, 2024
Trade discount	$	13,075	$	13,421
Other long-term liabilities		53		44
Total other long-term liabilities	$	13,128	$	13,465